DK3810281T3 - Fremgangsmåder til behandling af cancer med bispecifikke antI-CD3XMUC16-antistoffer og anti-PD-1-antistoffer - Google Patents
Fremgangsmåder til behandling af cancer med bispecifikke antI-CD3XMUC16-antistoffer og anti-PD-1-antistoffer Download PDFInfo
- Publication number
- DK3810281T3 DK3810281T3 DK19739472.9T DK19739472T DK3810281T3 DK 3810281 T3 DK3810281 T3 DK 3810281T3 DK 19739472 T DK19739472 T DK 19739472T DK 3810281 T3 DK3810281 T3 DK 3810281T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- cd3xmuc16
- methods
- treating cancer
- bispecific
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688251P | 2018-06-21 | 2018-06-21 | |
| PCT/US2019/038163 WO2019246356A1 (en) | 2018-06-21 | 2019-06-20 | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3810281T3 true DK3810281T3 (da) | 2024-08-19 |
Family
ID=67254001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19739472.9T DK3810281T3 (da) | 2018-06-21 | 2019-06-20 | Fremgangsmåder til behandling af cancer med bispecifikke antI-CD3XMUC16-antistoffer og anti-PD-1-antistoffer |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11254752B2 (da) |
| EP (2) | EP3810281B1 (da) |
| JP (1) | JP7403480B2 (da) |
| KR (1) | KR20210023981A (da) |
| CN (1) | CN112312970A (da) |
| AU (1) | AU2019290170A1 (da) |
| BR (1) | BR112020025476A2 (da) |
| CA (1) | CA3103887A1 (da) |
| CL (1) | CL2020003256A1 (da) |
| DK (1) | DK3810281T3 (da) |
| EA (1) | EA202190088A1 (da) |
| FI (1) | FI3810281T3 (da) |
| IL (1) | IL279251A (da) |
| MA (1) | MA52962A (da) |
| MX (1) | MX2020013905A (da) |
| PH (1) | PH12020552115A1 (da) |
| PT (1) | PT3810281T (da) |
| RS (1) | RS65886B1 (da) |
| SG (1) | SG11202012137UA (da) |
| TW (1) | TW202005985A (da) |
| WO (1) | WO2019246356A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US10556952B2 (en) | 2015-03-30 | 2020-02-11 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to Fc gamma receptors |
| CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| JP2024506831A (ja) | 2021-01-28 | 2024-02-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイトカイン放出症候群を治療するための組成物及び方法 |
| EP4308160A2 (en) * | 2021-03-18 | 2024-01-24 | Memorial Sloan-Kettering Cancer Center | Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors |
| EP4397320A1 (en) | 2021-08-31 | 2024-07-10 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product |
| AU2022398486A1 (en) * | 2021-11-24 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies |
| WO2023133280A1 (en) * | 2022-01-07 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| CN118510810A (zh) | 2022-01-10 | 2024-08-16 | 南京维立志博生物科技有限公司 | 一种抗体及其用途 |
| TW202400232A (zh) * | 2022-03-16 | 2024-01-01 | 日商第一三共股份有限公司 | 多特異性分子與免疫檢查點抑制劑之組合 |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| US20240277844A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| IL147972A0 (en) | 1999-08-23 | 2002-09-12 | Dana Farber Cancer Inst Inc Ge | Pd-1, a receptor for b7-4 and uses therefor |
| ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP2170959B1 (en) | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| SI2350129T1 (sl) | 2008-08-25 | 2015-11-30 | Amplimmune, Inc. | Sestavki PD-1 antagonistov in postopek njihove uporabe |
| EP3916011A1 (en) | 2009-06-26 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| ES2901133T3 (es) * | 2015-09-23 | 2022-03-21 | Regeneron Pharma | Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos |
| WO2017112775A1 (en) * | 2015-12-22 | 2017-06-29 | Regeneron Pharmaceuticals, Inc. | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
| TW202408578A (zh) * | 2016-05-13 | 2024-03-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| RS63660B1 (sr) | 2016-09-23 | 2022-11-30 | Regeneron Pharma | Anti-muc16 (mucin 16) antitela |
| BR112019010878A2 (pt) * | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
-
2019
- 2019-06-19 TW TW108121196A patent/TW202005985A/zh unknown
- 2019-06-20 JP JP2020570938A patent/JP7403480B2/ja active Active
- 2019-06-20 BR BR112020025476-2A patent/BR112020025476A2/pt unknown
- 2019-06-20 WO PCT/US2019/038163 patent/WO2019246356A1/en active Application Filing
- 2019-06-20 PT PT197394729T patent/PT3810281T/pt unknown
- 2019-06-20 EA EA202190088A patent/EA202190088A1/ru unknown
- 2019-06-20 RS RS20240959A patent/RS65886B1/sr unknown
- 2019-06-20 KR KR1020217000649A patent/KR20210023981A/ko unknown
- 2019-06-20 MA MA052962A patent/MA52962A/fr unknown
- 2019-06-20 FI FIEP19739472.9T patent/FI3810281T3/fi active
- 2019-06-20 DK DK19739472.9T patent/DK3810281T3/da active
- 2019-06-20 US US16/447,067 patent/US11254752B2/en active Active
- 2019-06-20 CA CA3103887A patent/CA3103887A1/en active Pending
- 2019-06-20 EP EP19739472.9A patent/EP3810281B1/en active Active
- 2019-06-20 CN CN201980040564.9A patent/CN112312970A/zh active Pending
- 2019-06-20 AU AU2019290170A patent/AU2019290170A1/en active Pending
- 2019-06-20 EP EP24176671.6A patent/EP4424712A2/en active Pending
- 2019-06-20 SG SG11202012137UA patent/SG11202012137UA/en unknown
- 2019-06-20 MX MX2020013905A patent/MX2020013905A/es unknown
-
2020
- 2020-12-07 IL IL279251A patent/IL279251A/en unknown
- 2020-12-10 PH PH12020552115A patent/PH12020552115A1/en unknown
- 2020-12-16 CL CL2020003256A patent/CL2020003256A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA52962A (fr) | 2021-04-28 |
| US20190389966A1 (en) | 2019-12-26 |
| AU2019290170A1 (en) | 2021-01-07 |
| MX2020013905A (es) | 2021-03-09 |
| IL279251A (en) | 2021-01-31 |
| EP3810281A1 (en) | 2021-04-28 |
| JP7403480B2 (ja) | 2023-12-22 |
| US11254752B2 (en) | 2022-02-22 |
| EP3810281B1 (en) | 2024-07-24 |
| KR20210023981A (ko) | 2021-03-04 |
| CA3103887A1 (en) | 2019-12-26 |
| JP2021528423A (ja) | 2021-10-21 |
| CN112312970A (zh) | 2021-02-02 |
| BR112020025476A2 (pt) | 2021-03-16 |
| CL2020003256A1 (es) | 2021-04-30 |
| EA202190088A1 (ru) | 2021-03-22 |
| SG11202012137UA (en) | 2021-01-28 |
| PH12020552115A1 (en) | 2021-08-02 |
| FI3810281T3 (fi) | 2024-08-14 |
| RS65886B1 (sr) | 2024-09-30 |
| WO2019246356A1 (en) | 2019-12-26 |
| EP4424712A2 (en) | 2024-09-04 |
| TW202005985A (zh) | 2020-02-01 |
| PT3810281T (pt) | 2024-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3810281T3 (da) | Fremgangsmåder til behandling af cancer med bispecifikke antI-CD3XMUC16-antistoffer og anti-PD-1-antistoffer | |
| DK3565844T3 (da) | Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer | |
| DK3394103T3 (da) | Kombination af anti-PD-1-antistoffer og bispecifikke anti-CD20-/anti-CD3-antistoffer til cancerbehandling | |
| DK3455259T3 (da) | Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling | |
| ZA202004735B (en) | Anti-pd-1 antibodies and methods of treatment | |
| DK3551660T5 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
| SG11202011461TA (en) | Anti-pvrig/anti-tigit bispecific antibodies and methods of use | |
| DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
| DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3826667T3 (da) | Claudin6-antistoffer og fremgangsmåder til behandling af kræft | |
| DK3788044T3 (da) | RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf | |
| DK3601358T5 (da) | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf | |
| IL278772A (en) | Antibodies against 40-OX and methods of use | |
| DK3353212T3 (da) | Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf | |
| DK3178849T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| DK3280440T5 (da) | Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| IL266990A (en) | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens | |
| DK3250610T3 (da) | Fcrn-antistoffer og fremgangsmåder til anvendelse heraf | |
| ZA202005223B (en) | Methods of treating cancers with antagonistic anti-pd-1 antibodies | |
| DK3426777T3 (da) | Kombinationsvektorer og fremgangsmåder til behandling af cancer | |
| DK3491025T3 (da) | Fcrn-antistoffer og anvendelsesmetoder heraf | |
| DK3618928T3 (da) | Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| DK3720879T3 (da) | Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer | |
| IL276253A (en) | Bispecific antigen binding molecules and methods of use |